Brilinta shows promise in phase III clinical trial
Results of a phase III clinical trial suggest that dual antiplatelet therapy may improve outcomes for patients with established coronary artery disease (CAD) and type 2 diabetes....
List view / Grid view
Results of a phase III clinical trial suggest that dual antiplatelet therapy may improve outcomes for patients with established coronary artery disease (CAD) and type 2 diabetes....
A study has found that when compared with other drugs, canagliflozin may not be associated with fractures in patients with diabetes...
The Endocrine Society has reported that increasing costs of insulin means that people are often deciding to forgo necessary treatment...
Lixisenatide has shown prevention of kidney damage in patients with type 2 diabetes or cardiovascular disease through a study by the EASD...
A new observational study has identified no benefit from prescribing statins to healthy pensioners aged over 75 to prevent heart disease...
Two companies will work closely together on future development, distribution, promotion, access, marketing and sales of Invokana (canagliflozin) for type 2 diabetes...
Women who have gestational diabetes mellitus during pregnancy have a higher than usual risk of developing type 2 diabetes, hypertension, and ischemic heart disease in the future...
Scientists have developed an online interactive app to help motivate patients to be more active in managing their disease...
Health Canada has approved Ozempic to improve glycemic control in adults with type 2 diabetes mellitus when metformin is not tolerated or contraindicated...
The FDA has approved Admelog, a short-acting insulin indicated to improve control in blood sugar levels in diabetes...
Researchers have identified a type of human leukocyte antigen (HLA) that is associated with the skin disease bullous pemphigoid (BP) in diabetic patients administered with DPP-4 inhibitory drugs.
The FDA has approved Bydureon BCise for adults with type-2 diabetes whose blood sugar remains uncontrolled on one or more oral medicines...
Researchers have identified that the drug semaglutide resulted in better glycemic control than placebo for patients with type 2 diabetes...
3 April 2017 | By Dr David Pugh, IDTechEx
The latest 2017 pipelines explores new emerging methods of glucose monitoring, analysing these technologies in the new report from IDTechEx Research...
Results from Sanofi’s Phase III LixiLan-O and LixiLan-L clinical trials have been presented at the American Diabetes Association 76th Scientific Sessions.